This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
by Zacks Equity Research
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
by Zacks Equity Research
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
by Zacks Equity Research
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma
by Zacks Equity Research
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
Alexion's Ultomiris Gets FDA Approval for New Formulation
by Zacks Equity Research
Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Canopy Growth (CGC) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Axovant's Gene Therapy Gets Rare Pediatric Disease Status
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.
Amgen Down on Unsatisfactory Heart Failure Drug Study Results
by Zacks Equity Research
Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.
Novo Nordisk Raises Sales & Operating Profit Outlook for 2020
by Zacks Equity Research
Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.
BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq
by Zacks Equity Research
The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.
Kindred Shares Up on Expansion of Agreement With Vaxart
by Zacks Equity Research
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
Iovance Stock Down on Delay in Filing for Melanoma Candidate
by Zacks Equity Research
Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.
Alector (ALEC) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Increased Earnings Estimates Seen for AVEO Pharmaceuticals (AVEO): Can It Move Higher?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
AVEO's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.
AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix
by Zacks Equity Research
AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.
AVEO (AVEO) Up 20.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO's NDA for Fotivda on Track, FDA Verdict Due Next Year
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.
Rhythm (RYTM) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.